Information Provided By:
Fly News Breaks for October 24, 2017
TECH
Oct 24, 2017 | 04:58 EDT
Citi analyst Daniel Arias raised his price target for Bio-Techne to $145 saying he sees room for more upside even with the shares up 20% year-to-date. The analyst views the company as "one of the better set-up stories" in the tools space and believes the shares can "grind higher" into fiscal 2018. He keeps a Buy rating on the name.
News For TECH From the Last 2 Days
There are no results for your query TECH
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.